# No Association between Ischemic Stroke and Portal Vein Thrombosis in Liver Cirrhosis

Authors: Kexin Zheng; Xiaozhong Guo; Fangfang Yi; Le Wang; Andrea Mancuso; Xingshun Qi
Journal: BioMed Research International
 (2020)

---

## Abstract

Background and Aims. There seems to be a higher risk of ischemic stroke and portal vein thrombosis in liver cirrhosis. Both of them may be associated with hypercoagulability. We aim to explore the association between ischemic stroke and portal vein thrombosis in liver cirrhosis. Study Design and Methods. We selected patients from our prospectively established database of liver cirrhosis from December 2014 to July 2019. The difference between patients with and without stroke was compared. A 1 : 1 propensity score matching (PSM) analysis was performed to adjust the effect of age, sex, Child-Pugh score, and MELD score on our statistical results. Results. There were 349 cirrhotic patients in the cross-sectional study. The prevalence of stroke, ischemic stroke, hemorrhagic stroke, and portal vein thrombosis was 8.88% (31/349), 8.31% (29/349), 1.15% (4/349), and 28.65% (100/349) in liver cirrhosis, respectively. Patients with ischemic stroke were significantly older and had significantly higher proportions of alcohol abuse, smoking, and arterial hypertension and higher levels of white blood cell and low-density lipoprotein. However, statistical analyses with and without PSM did not find any significant association between ischemic stroke and portal vein thrombosis in patients with liver cirrhosis. Conclusion. Ischemic stroke might not be associated with portal vein thrombosis in liver cirrhosis.


---

## Body

## 1. Introduction

Stroke, an acute cerebrovascular disease, is the leading cause of death and disability worldwide, especially in Asia [1]. It has been traditionally considered that stroke, especially atherosclerotic ischemic stroke, is closely associated with hypercoagulability, such as increased homocysteine and lipoprotein(a) and antiphospholipid antibodies [2]. Liver cirrhosis, which often has an increased level of factor VIII (FVIII) and decreased level of protein C (PC) and mean lifetime of platelet, has been also considered as a potential risk factor of stroke [3, 4]. Besides, it is associated with the development of venous thromboembolism, including portal vein thrombosis [5].Development of stroke and portal vein thrombosis in liver cirrhosis seems to share several common pathophysiological mechanisms or risk factors. First, both of them relate to the hypercoagulability of cirrhosis [3], which is characterized as reduced PC in combination with increased FVIII [6]. Second, both stroke and portal vein thrombosis relate to portal hypertension. Reduced portal vein flow velocity and portosystemic collateral shunt are common characteristics of portal hypertension, which aggravate the development of portal vein thrombosis [7]. Ascites and esophageal variceal bleeding are major clinical manifestations of portal hypertension, which result in the decrease of effective circulating blood volume and hypovolemia of organs, thereby leading to ischemic stroke [8]. Third, diabetic patients have approximately 2-4 times higher risk of ischemic stroke than those with normal glucose levels [9]. Meanwhile, diabetes is also an independent risk factor of portal vein thrombosis [10]. Fourth, antiphospholipid syndrome may increase the risk of ischemic stroke as well as portal vein thrombosis. Irregular thickening of the valve leaflets secondary to antiphospholipid syndrome and lupus anticoagulants are significant risk factor of stroke [11]. Meanwhile, anticardiolipin antibodies levels were higher in liver cirrhosis with portal vein thrombosis than that without portal vein thrombosis [12, 13]. Fifth, Helicobacter pylori not only acts as a promoter of antiphospholipid syndrome through chronic inflammation [14] but also stimulates the production of plasminogen activator inhibitor-2, which has an effect on increasing the risk of ischemic stroke and portal vein thrombosis [15]. Sixth, methylenetetrahydrofolate reductase (MTHFR) mutation is a common risk factor of stroke and portal vein thrombosis, which relates to endothelial damage [16]. MTHFR activity is reduced in the patients with MTHFR mutations, thereby leading to the deficiency of folate and hyperhomocysteinemia. MTHFR is responsible for catalyzing the reduction of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate in the folate cycle, which further produces the active form of folate for the remethylation of homocysteine to methionine [17]. There is a significant association between hyperhomocysteinemia and stroke [18]. An elevated homocysteine concentration significantly increases the risk of stroke [19]. Folic acid supplementation is effective in stroke prevention [20]. And MTHFR A1298C mutation is associated with increased risk of ischemic stroke [21]. On the other hand, MTHFR C677T mutation may increase the risk of portal vein thrombosis in cirrhotic patients [22]. The prevalence of hyperhomocysteinemia is significantly higher in cirrhotic patients with portal vein thrombosis than those without portal vein thrombosis [22]. Taken together, we hypothesized that cirrhotic patients with stroke might have an increased risk of portal vein thrombosis. Herein, this retrospective study was aimed at elucidating this issue.


## 2. Methods

### 2.1. Study Design

The study population was selected from our prospectively established database of cirrhotic patients without malignancy of the Department of Gastroenterology of our hospital from December 2014 to July 2019. All included patients must undergo abdominal enhanced computed tomography or magnetic resonance and endoscopy at their first enrollment. Age, sex, and the etiologies of liver cirrhosis were not limited. Repeated admissions of the same patients were excluded. Patients with abdominal surgery, including splenectomy, and splenic arterial embolization were excluded. Patients in whom a history of stroke cannot be accurately evaluated were excluded. Patients in whom the location of portal vein thrombosis cannot be evaluated due to missing images were also excluded. The study protocol was approved by the Medical Ethics Committee of our hospital. The ethical approval number was k(2019)39. The patient’s informed consent was not required in our retrospective study.


### 2.2. Medical Data

The data were collected as follows.(1)
Demographic information: age and sex(2)
Systolic and diastolic blood pressure at admission(3)
Etiologies of liver diseases: hepatitis B virus (HBV), hepatitis C virus (HCV), alcohol abuse, drug related liver diseases, Budd-Chiari syndrome, and autoimmune liver diseases, etc.(4)
Clinical presentations at admission: hepatic encephalopathy, acute gastrointestinal bleeding, and ascites(5)
Medical history: venous thrombus, hematological diseases, diabetes mellitus, arterial hypertension, smoking, and cardiac diseases(6)
Laboratory tests: red blood cell, hemoglobin, white blood cell, platelet, total bilirubin, direct bilirubin, indirect bilirubin, albumin, alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase,γ-glutamyl transpeptidase, blood urea nitrogen, serum, creatinine, potassium, sodium homocysteine, total cholesterol, triglyceride, high-density lipoprotein, low-density lipoprotein, lipoprotein α, prothrombin time, international normalized ratio (INR), activated partial thromboplastin time, D-dimer, antithrombin III, PC activity, and PS activity(7)
Child-Pugh and model for the end-stage liver diseases (MELD) score


### 2.3. Definitions

Stroke was defined as previous history of stroke as well as a diagnosis of stroke at their enrollment. Type of stroke was divided into ischemic and hemorrhagic stroke according to previous medical history, clinical manifestations, and/or the results of brain imaging examination. Location of portal vein thrombosis was determined by our study group via the images of enhanced computed tomography or magnetic resonance. Portal system vessels include left portal vein (LPV), right portal vein (RPV), main portal vein (MPV), confluence of superior mesenteric vein (SMV) and splenic vein (SV), SMV, and SV.


### 2.4. Statistical Analyses

Continuous and categorical variables were expressed by median (range) and frequency (percentage), respectively. The difference between patients with and without stroke was compared using Mann-WhitneyU test and χ2 test, as appropriate. A 1 : 1 propensity score matching (PSM) analysis was performed to adjust the effect of age, sex, Child-Pugh score, and MELD score on our statistical results. If a p value was less than 0.05, it would be considered statistically significant. SPSS statistical software, version 22.0 (IBM Corp, Armonk, NY, USA), was employed to perform statistical analyses.


## 2.1. Study Design

The study population was selected from our prospectively established database of cirrhotic patients without malignancy of the Department of Gastroenterology of our hospital from December 2014 to July 2019. All included patients must undergo abdominal enhanced computed tomography or magnetic resonance and endoscopy at their first enrollment. Age, sex, and the etiologies of liver cirrhosis were not limited. Repeated admissions of the same patients were excluded. Patients with abdominal surgery, including splenectomy, and splenic arterial embolization were excluded. Patients in whom a history of stroke cannot be accurately evaluated were excluded. Patients in whom the location of portal vein thrombosis cannot be evaluated due to missing images were also excluded. The study protocol was approved by the Medical Ethics Committee of our hospital. The ethical approval number was k(2019)39. The patient’s informed consent was not required in our retrospective study.


## 2.2. Medical Data

The data were collected as follows.(1)
Demographic information: age and sex(2)
Systolic and diastolic blood pressure at admission(3)
Etiologies of liver diseases: hepatitis B virus (HBV), hepatitis C virus (HCV), alcohol abuse, drug related liver diseases, Budd-Chiari syndrome, and autoimmune liver diseases, etc.(4)
Clinical presentations at admission: hepatic encephalopathy, acute gastrointestinal bleeding, and ascites(5)
Medical history: venous thrombus, hematological diseases, diabetes mellitus, arterial hypertension, smoking, and cardiac diseases(6)
Laboratory tests: red blood cell, hemoglobin, white blood cell, platelet, total bilirubin, direct bilirubin, indirect bilirubin, albumin, alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase,γ-glutamyl transpeptidase, blood urea nitrogen, serum, creatinine, potassium, sodium homocysteine, total cholesterol, triglyceride, high-density lipoprotein, low-density lipoprotein, lipoprotein α, prothrombin time, international normalized ratio (INR), activated partial thromboplastin time, D-dimer, antithrombin III, PC activity, and PS activity(7)
Child-Pugh and model for the end-stage liver diseases (MELD) score


## 2.3. Definitions

Stroke was defined as previous history of stroke as well as a diagnosis of stroke at their enrollment. Type of stroke was divided into ischemic and hemorrhagic stroke according to previous medical history, clinical manifestations, and/or the results of brain imaging examination. Location of portal vein thrombosis was determined by our study group via the images of enhanced computed tomography or magnetic resonance. Portal system vessels include left portal vein (LPV), right portal vein (RPV), main portal vein (MPV), confluence of superior mesenteric vein (SMV) and splenic vein (SV), SMV, and SV.


## 2.4. Statistical Analyses

Continuous and categorical variables were expressed by median (range) and frequency (percentage), respectively. The difference between patients with and without stroke was compared using Mann-WhitneyU test and χ2 test, as appropriate. A 1 : 1 propensity score matching (PSM) analysis was performed to adjust the effect of age, sex, Child-Pugh score, and MELD score on our statistical results. If a p value was less than 0.05, it would be considered statistically significant. SPSS statistical software, version 22.0 (IBM Corp, Armonk, NY, USA), was employed to perform statistical analyses.


## 3. Results

### 3.1. Patients’ Characteristics

Overall, 349 cirrhotic patients were included, of whom 31 (8.88%) had stroke and 318 did not have stroke. Among the 31 patients with stroke, 29 (8.31%), 4 (1.15%), and 2 (0.57%) patients had ischemic stroke, hemorrhagic stroke, and hemorrhagic combined with ischemic stroke, respectively. The prevalence of portal vein thrombosis was 28.65% (100/349). The prevalence of thrombosis within LPV, RPV, MPV, confluence of SMV and SV, SMV, and SV was 8.31% (29/349), 9.46% (33/349), 16.05% (56/349), 11.46% (40/349), 15.19% (53/349), and 3.72% (13/349), respectively.


### 3.2. Comparison between Liver Cirrhosis with and without Stroke

Compared with the patients without stroke, those with stroke were significantly older (60.21 versus 54.21 years,p=0.003) and had significantly higher proportions of alcohol abuse (64.5% versus 43.7%, p=0.026), smoking (67.7% versus 42.5%, p=0.007), and arterial hypertension (38.7% versus 12.9%, p<0.001) and higher levels of white blood cell (4.50 versus 3.40×109/L, p=0.001) and low-density lipoprotein (2.12 versus 1.65 mmol/L, p=0.013) (Table 1). There was no difference in the prevalence of portal vein thrombosis and location of portal vein thrombosis between patients with and without stroke.Table 1
Comparison between patients with and without stroke.
VariablesStrokeNo strokep valueNo. ptsMedian (range) or frequency (percentage)No. ptsMedian (range) or frequency (percentage)Age (years)3160.21 (38.72-77.30)31854.21 (20.57-88.73)0.003Gender (male)3125 (80.6%)318230 (72.3%)0.319Systolic blood pressure (mmHg)31125.00 (90.00-173.00)317122.00 (83.00-193.00)0.594Diastolic blood pressure (mmHg)3175.00 (50.00-117.00)31775.00 (34.00-118.00)0.844Etiology of liver diseasesHepatitis B virus infection3110 (32.3%)318125 (39.3%)0.442Hepatitis C virus infection311 (3.2%)31820 (6.3%)0.494Alcohol abuse3120 (64.5%)318139 (43.7%)0.026Drug related314 (12.9%)31821 (6.6%)0.194Budd-Chiari syndrome310 (0.0%)3181 (0.3%)0.755Autoimmune liver diseases310 (0.0%)31822 (6.9%)0.130Clinical presentations at admissionHepatic encephalopathy311 (3.2%)3188 (2.5%)0.812Acute gastrointestinal bleeding319 (29.0%)318101 (31.8%)0.755Ascites (no/mild/moderate-severe)3116 (51.6%)/8 (25.8%)/7 (22.6%)318127 (39.9%)/108 (34.0%)/83 (26.1%)0.440HistoryHistory of venous thrombus310 (0.0%)3187 (2.2%)0.404History of hematological diseases311 (3.2%)3185 (1.6%)0.499History of diabetes mellitus318 (25.8%)31851 (16.0%)0.166History of arterial hypertension3112 (38.7%)31841 (12.9%)<0.001History of smoking3121 (67.7%)318135 (42.5%)0.007History of cardiac diseases315 (16.1%)31823 (7.2%)0.082Laboratory testsRed blood cell (1012/L)313.33 (1.15-5.20)3183.27 (1.45-5.46)0.432Hemoglobin (g/L)31101.00 (37.00-174.00)31892.50 (28.00-156.00)0.104White blood cell (109/L)314.50 (1.30-22.70)3183.40 (0.70-20.80)0.001Platelet (109/L)3186.00 (37.00-377.00)31873.00 (19.00-470.00)0.169Total bilirubin (μmol/L)3121.10 (5.70-132.70)31822.00 (5.20-281.10)0.775Direct bilirubin (μmol/L)318.90 (2.00-78.20)3189.45 (2.00-210.40)0.920Indirect bilirubin (μmol/L)3111.90 (3.60-76.00)31811.30 (3.20-93.80)0.677Albumin (g/L)3132.50 (22.10-44.50)31632.35 (14.20-50.60)0.482Alanine aminotransferase (U/L)3120.06 (7.74-176.68)31824.34 (4.23-613.24)0.396Aspartate aminotransferase (U/L)3130.73 (9.74-143.00)31834.33 (9.63-761.63)0.824Alkaline phosphatase (U/L)3188.23 (28.83-337.00)31894.40 (31.00-983.93)0.641γ-Glutamyl transpeptidase (U/L)3170.00 (10.00-1779.18)31842.64 (7.54-1283.02)0.121Blood urea nitrogen (mmol/L)315.85 (3.52-47.25)3145.31 (0.64-24.80)0.226Serum creatinine (μmol/L)3170.90 (42.82-267.63)31464.07 (23.83-178.55)0.228Potassium (mmol/L)314.01 (2.80-5.41)3173.86 (2.42-5.28)0.066Sodium (mmol/L)31138.00 (134.10-145.50)317138.90 (118.00-152.90)0.574Homocysteine (μmol/L)1610.49 (6.70-31.79)1709.16 (1.59-102.81)0.145Total cholesterol (mmol/L)203.68 (1.82-6.58)2083.11 (1.14-6.29)0.148Triglyceride (mmol/L)200.83 (0.41-6.22)2080.85 (0.35-4.81)0.661High-density lipoprotein (mmol/L)200.93 (0.47-1.39)2080.94 (0.24-2.29)0.766Low-density lipoprotein (mmol/L)202.12 (0.99-4.37)2081.65 (0.47-4.06)0.013Lipoproteinα (mg/L)2088.70 (17.90-466.40)20863.20 (3.60-911.40)0.108Prothrombin time (seconds)3115.30 (12.70-20.40)31415.70 (10.30-28.00)0.188International normalized ratio311.23 (0.99-1.75)3141.27 (0.89-2.77)0.164Activated partial thromboplastin time (seconds)3140.20 (19.80-53.80)31439.90 (23.10-71.30)0.808D-dimer (mg/L)191.32 (0.16-10.56)2520.86 (0.10-46.17)0.873Antithrombin III (%)1165.30 (40.00-84.00)11863.00 (21.00-123.00)0.933Protein C activity (%)657.30 (49.80-75.10)5459.65 (24.00-119.30)0.721Protein S activity (%)661.55 (55.60-73.30)5463.50 (20.70-123.60)0.873Child-Pugh score317.00 (5.00-10.00)3137.00 (5.00-13.00)0.837MELD score3110.46 (7.23-18.00)31210.41 (6.43-30.03)0.736Portal vein thrombosis318 (25.8%)31892 (28.9%)0.713LPV4 (12.9%)25 (7.9%)0.332RPV2 (6.5%)31 (9.7%)0.549MPV4 (12.9%)52 (16.4%)0.617Confluence of SMV and SV5 (16.1%)35 (11.0%)0.393SMV2 (6.5%)51 (16.0%)0.156SV0 (0.0%)13 (4.1%)0.251No. pts: number of patients; MELD: model for the end-stage liver diseases; LPV: left portal vein; RPV: right portal vein; MPV: main portal vein; SMV: superior mesenteric vein; SV: splenic vein.


### 3.3. Comparison between Cirrhotic Patients with Ischemic Stroke and Those without Stroke

Compared with the patients without stroke, those with ischemic stroke were significantly older (61.08 versus 54.21 years,p=0.002) and had significantly higher proportions of alcohol abuse (65.5% versus 43.7%, p=0.024), smoking (69.0% versus 42.5%, p=0.006), and arterial hypertension (37.9% versus 12.9%, p<0.001) and higher levels of white blood cell (4.90 versus 3.40×109/L, p<0.001), potassium (4.05 versus 3.86 mmol/L, p=0.047), and low-density lipoprotein (2.12 versus 1.65 mmol/L, p=0.008) (Table 2). There was no significant difference in the prevalence of portal vein thrombosis and location of portal vein thrombosis between patients with and without stroke.Table 2
Comparison between patients with ischemic stroke and those without stroke.
VariablesIschemic strokeNo strokep valueNo. ptsMedian (range) or frequency (percentage)No. ptsMedian (range) or frequency (percentage)Age (years)2961.08 (38.72-77.30)31854.21 (20.57-88.73)0.002Gender (male)2923 (79.3%)318230 (72.3%)0.418Systolic blood pressure (mmHg)29124.00 (90.00-173.00)317122.00 (83.00-193.00)0.975Diastolic blood pressure (mmHg)2973.00 (50.00-108.00)31775.00 (34.00-118.00)0.700Etiology of liver diseasesHepatitis B virus infection2910 (34.5%)318125 (39.3%)0.610Hepatitis C virus infection291 (3.4%)31820 (6.3%)0.539Alcohol abuse2919 (65.5%)318139 (43.7%)0.024Drug related294 (13.8%)31821 (6.6%)0.152Budd-Chiari syndrome290 (0.0%)3181 (0.3%)0.762Autoimmune liver diseases290 (0.0%)31822 (6.9%)0.143Clinical presentations at admissionHepatic encephalopathy291 (3.4%)3188 (2.5%)0.762Acute gastrointestinal bleeding298 (27.6%)318101 (31.8%)0.643Ascites (no/mild/moderate-severe)2915 (51.7%)/7 (24.1%)/7 (24.1%)318127 (39.9%)/108 (34.0%)/83 (26.1%)0.424HistoryHistory of venous thrombus290 (0.0%)3187 (2.2%)0.420History of hematological diseases291 (3.4%)3185 (1.6%)0.458History of diabetes mellitus298 (27.6%)31851 (16.0%)0.113History of arterial hypertension2911 (37.9%)31841 (12.9%)<0.001History of smoking2920 (69.0%)318135 (42.5%)0.006History of cardiac diseases295 (17.2%)31823 (7.2%)0.058Laboratory testsRed blood cell (1012/L)293.33 (1.15-5.20)3183.27 (1.45-5.46)0.471Hemoglobin (g/L)29101.00 (37.00-174.00)31892.50 (28.00-156.00)0.126White blood cell (109/L)294.90 (1.30-22.70)3183.40 (0.70-20.80)<0.001Platelet (109/L)2990.00 (37.00-377.00)31873.00 (19.00-470.00)0.068Total bilirubin (μmol/L)2925.10 (5.70-132.70)31822.00 (5.20-281.10)0.606Direct bilirubin (μmol/L)299.00 (2.00-78.20)3189.45 (2.00-210.40)0.892Indirect bilirubin (μmol/L)2912.40 (3.60-76.00)31811.30 (3.20-93.80)0.576Albumin (g/L)2931.10 (22.10-44.50)31632.35 (14.20-50.60)0.401Alanine aminotransferase (U/L)2921.33 (7.74-176.68)31824.34 (4.23-613.24)0.643Aspartate aminotransferase (U/L)2931.44 (9.74-143.00)31834.33 (9.63-761.63)0.902Alkaline phosphatase (U/L)2992.49 (28.83-337.00)31894.40 (31.00-983.93)0.921γ-Glutamyl transpeptidase (U/L)2970.00 (10.00-1779.18)31842.64 (7.54-1283.02)0.073Blood urea nitrogen (mmol/L)295.82 (3.52-47.25)3145.31 (0.64-24.80)0.271Serum creatinine (μmol/L)2970.90 (42.82-267.63)31464.07 (23.83-178.55)0.253Potassium (mmol/L)294.05 (2.80-5.41)3173.86 (2.42-5.28)0.047Sodium (mmol/L)29137.90 (134.10-145.50)317138.90 (118.00-152.90)0.430Homocysteine (μmol/L)1510.47 (6.70-31.79)1709.16 (1.59-102.81)0.179Total cholesterol (mmol/L)193.77 (1.82-6.58)2083.11 (1.14-6.29)0.104Triglyceride (mmol/L)190.86 (0.47-6.22)2080.85 (0.35-4.81)0.414High-density lipoprotein (mmol/L)190.92 (0.47-1.39)2080.94 (0.24-2.29)0.762Low-density lipoprotein (mmol/L)192.12 (0.99-4.37)2081.65 (0.47-4.06)0.008Lipoproteinα (mg/L)1991.70 (17.90-466.40)20863.20 (3.60-911.40)0.114Prothrombin time (seconds)2915.30 (12.70-20.40)31415.70 (10.30-28.00)0.198International normalized ratio291.23 (0.99-1.75)3141.27 (0.89-2.77)0.170Activated partial thromboplastin time (seconds)2940.00 (19.80-53.80)31439.90 (23.10-71.30)0.952D-dimer (mg/L)191.32 (0.16-10.56)2520.86 (0.10-46.17)0.873Antithrombin III (%)1165.30 (40.00-84.00)11863.00 (21.00-123.00)0.933Protein C activity (%)657.30 (49.80-75.10)5459.65 (24.00-119.30)0.721Protein S activity (%)661.55 (55.60-73.30)5463.50 (20.70-123.60)0.873Child-Pugh score297.00 (5.00-10.00)3137.00 (5.00-13.00)0.749MELD score2910.46 (7.23-18.00)31210.41 (6.43-30.03)0.892Portal vein thrombosis297 (24.1%)31892 (28.9%)0.584LPV3 (10.3%)25 (7.9%)0.638RPV2 (6.9%)31 (9.7%)0.616MPV4 (13.8%)52 (16.4%)0.720Confluence of SMV and SV5 (17.2%)35 (11.0%)0.314SMV2 (6.9%)51 (16.0%)0.190SV0 (0.0%)13 (4.1%)0.267No. pts: number of patients; MELD: model for the end-stage liver diseases; LPV: left portal vein; RPV: right portal vein; MPV: main portal vein; SMV: superior mesenteric vein; SV: splenic vein.


### 3.4. PSM Analysis between Cirrhotic Patients with Ischemic Stroke and Those without Stroke

Twenty-eight patients were matched in each group after a 1 : 1 PSM analysis (Table3). There was no significant difference in demographics, etiology of liver disease, laboratory tests, clinical presentations, Child-Pugh score, and MELD score between the two groups. Notably, we still did not find any significant association between ischemic stroke and portal vein thrombosis.Table 3
Characteristics of cirrhotic patients with ischemic stroke and those without stroke after propensity score matching.
VariablesOverall (n=56)Ischemic stroke (n=28)No stroke (n=28)p valueAge (years)59.68 (35.18-77.30)60.65 (38.72-77.30)58.44 (35.18-75.72)0.258Gender (male)47 (83.9%)22 (78.6%)25 (89.3%)0.275Systolic blood pressure (mmHg)125.00 (83.00-173.00)124.50 (90.00-173.00)126.50 (83.00-158.00)0.491Diastolic blood pressure (mmHg)75.50 (44.00-108.00)72.00 (50.00-108.00)81.00 (44.00-107.00)0.161Etiology of liver diseasesHepatitis B virus infection23 (41.1%)10 (35.7%)13 (46.4%)0.415Hepatitis C virus infection1 (1.8%)1 (3.6%)0 (0.0%)0.313Alcohol abuse35 (62.5%)18 (64.3%)17 (60.7%)0.783Drug related6 (10.7%)4 (14.3%)2 (7.1%)0.388Budd-Chiari syndrome0 (0.0%)0 (0.0%)0 (0.0%)NAAutoimmune liver diseases1 (1.8%)0 (0.0%)1 (3.6%)0.313Clinical presentations at admissionHepatic encephalopathy2 (3.6%)1 (3.6%)1 (3.6%)1.000Acute gastrointestinal bleeding13 (23.2%)7 (25.0%)6 (21.4%)0.752Ascites (no/mild/moderate-severe)27 (48.2%)/14 (25.0%)/15 (26.8%)15 (53.6%)/6 (21.4%)/7 (25.0%)12 (42.9%)/8 (28.6%)/8 (28.6%)0.710HistoryHistory of venous thrombus0 (0.0%)0 (0.0%)0 (0.0%)NAHistory of hematological diseases1 (1.8%)1 (3.6%)0 (0.0%)0.313History of diabetes mellitus12 (21.4%)8 (28.6%)4 (14.3%)0.193History of arterial hypertension13 (23.2%)10 (35.7%)3 (10.7%)0.027History of smoking39 (69.6%)20 (71.4%)19 (67.9%)0.771History of cardiac diseases8 (14.3%)5 (17.9%)3 (10.7%)0.445Laboratory testsRed blood cell (1012/L)3.52 (1.15-5.20)3.34 (1.15-5.20)3.69 (1.74-5.08)0.456Hemoglobin (g/L)109.00 (37.00-174.00)102.00 (37.00-174.00)110.50 (58.00-156.00)0.812White blood cell (109/L)4.25 (1.30-22.70)4.70 (1.30-22.70)4.05 (1.30-20.80)0.063Platelet (109/L)84.50 (37.00-423.00)88.00 (37.00-377.00)75.00 (37.00-423.00)0.961Total bilirubin (μmol/L)24.25 (5.70-132.70)25.30 (5.70-132.70)24.15 (6.60-47.00)0.718Direct bilirubin (μmol/L)9.55 (2.00-78.20)9.30 (2.00-78.20)9.60 (2.50-27.00)0.961Indirect bilirubin (μmol/L)12.45 (3.60-76.00)12.60 (3.60-76.00)12.35 (4.10-27.70)0.967Albumin (g/L)32.55 (22.10-46.20)30.75 (22.10-44.50)33.95 (24.50-46.20)0.201Alanine aminotransferase (U/L)24.79 (7.53-176.68)21.66 (7.74-176.68)25.59 (7.53-140.00)0.793Aspartate aminotransferase (U/L)33.94 (9.74-166.49)34.22 (9.74-143.00)33.94 (13.94-166.49)0.857Alkaline phosphatase (U/L)98.86 (28.83-337.00)93.60 (28.83-337.00)102.83 (52.28-337.00)0.481γ-Glutamyl transpeptidase (U/L)60.87 (10.00-1779.18)69.50 (10.00-1779.18)56.00 (10.93-552.26)0.611Blood urea nitrogen (mmol/L)5.62 (2.96-47.25)5.81 (3.52-47.25)5.38 (2.96-20.15)0.502Serum creatinine (μmol/L)66.64 (42.82-267.63)68.96 (42.82-267.63)64.19 (44.50-117.53)0.870Potassium (mmol/L)3.99 (2.74-5.41)4.03 (2.80-5.41)3.89 (2.74-4.75)0.517Sodium (mmol/L)138.50 (133.50-145.50)137.95 (134.10-145.50)139.65 (133.50-145.20)0.210Prothrombin time (seconds)15.30 (12.70-20.40)15.30 (12.70-20.40)15.25 (12.00-18.90)0.774International normalized ratio1.24 (0.93-1.75)1.24 (0.99-1.75)1.24 (0.93-1.64)0.883Activated partial thromboplastin time (seconds)40.10 (19.80-53.80)40.10 (19.80-53.80)40.30 (27.50-50.80)0.961Child-Pugh score7.00 (5.00-10.00)7.00 (5.00-10.00)7.00 (5.00-13.00)0.259MELD score10.43 (6.43-18.00)10.52 (7.23-18.00)10.32 (6.43-15.58)0.676Portal vein thrombosis14 (25.0%)7 (25.0%)7 (25.0%)1.000MELD: model for the end-stage liver diseases.


## 3.1. Patients’ Characteristics

Overall, 349 cirrhotic patients were included, of whom 31 (8.88%) had stroke and 318 did not have stroke. Among the 31 patients with stroke, 29 (8.31%), 4 (1.15%), and 2 (0.57%) patients had ischemic stroke, hemorrhagic stroke, and hemorrhagic combined with ischemic stroke, respectively. The prevalence of portal vein thrombosis was 28.65% (100/349). The prevalence of thrombosis within LPV, RPV, MPV, confluence of SMV and SV, SMV, and SV was 8.31% (29/349), 9.46% (33/349), 16.05% (56/349), 11.46% (40/349), 15.19% (53/349), and 3.72% (13/349), respectively.


## 3.2. Comparison between Liver Cirrhosis with and without Stroke

Compared with the patients without stroke, those with stroke were significantly older (60.21 versus 54.21 years,p=0.003) and had significantly higher proportions of alcohol abuse (64.5% versus 43.7%, p=0.026), smoking (67.7% versus 42.5%, p=0.007), and arterial hypertension (38.7% versus 12.9%, p<0.001) and higher levels of white blood cell (4.50 versus 3.40×109/L, p=0.001) and low-density lipoprotein (2.12 versus 1.65 mmol/L, p=0.013) (Table 1). There was no difference in the prevalence of portal vein thrombosis and location of portal vein thrombosis between patients with and without stroke.Table 1
Comparison between patients with and without stroke.
VariablesStrokeNo strokep valueNo. ptsMedian (range) or frequency (percentage)No. ptsMedian (range) or frequency (percentage)Age (years)3160.21 (38.72-77.30)31854.21 (20.57-88.73)0.003Gender (male)3125 (80.6%)318230 (72.3%)0.319Systolic blood pressure (mmHg)31125.00 (90.00-173.00)317122.00 (83.00-193.00)0.594Diastolic blood pressure (mmHg)3175.00 (50.00-117.00)31775.00 (34.00-118.00)0.844Etiology of liver diseasesHepatitis B virus infection3110 (32.3%)318125 (39.3%)0.442Hepatitis C virus infection311 (3.2%)31820 (6.3%)0.494Alcohol abuse3120 (64.5%)318139 (43.7%)0.026Drug related314 (12.9%)31821 (6.6%)0.194Budd-Chiari syndrome310 (0.0%)3181 (0.3%)0.755Autoimmune liver diseases310 (0.0%)31822 (6.9%)0.130Clinical presentations at admissionHepatic encephalopathy311 (3.2%)3188 (2.5%)0.812Acute gastrointestinal bleeding319 (29.0%)318101 (31.8%)0.755Ascites (no/mild/moderate-severe)3116 (51.6%)/8 (25.8%)/7 (22.6%)318127 (39.9%)/108 (34.0%)/83 (26.1%)0.440HistoryHistory of venous thrombus310 (0.0%)3187 (2.2%)0.404History of hematological diseases311 (3.2%)3185 (1.6%)0.499History of diabetes mellitus318 (25.8%)31851 (16.0%)0.166History of arterial hypertension3112 (38.7%)31841 (12.9%)<0.001History of smoking3121 (67.7%)318135 (42.5%)0.007History of cardiac diseases315 (16.1%)31823 (7.2%)0.082Laboratory testsRed blood cell (1012/L)313.33 (1.15-5.20)3183.27 (1.45-5.46)0.432Hemoglobin (g/L)31101.00 (37.00-174.00)31892.50 (28.00-156.00)0.104White blood cell (109/L)314.50 (1.30-22.70)3183.40 (0.70-20.80)0.001Platelet (109/L)3186.00 (37.00-377.00)31873.00 (19.00-470.00)0.169Total bilirubin (μmol/L)3121.10 (5.70-132.70)31822.00 (5.20-281.10)0.775Direct bilirubin (μmol/L)318.90 (2.00-78.20)3189.45 (2.00-210.40)0.920Indirect bilirubin (μmol/L)3111.90 (3.60-76.00)31811.30 (3.20-93.80)0.677Albumin (g/L)3132.50 (22.10-44.50)31632.35 (14.20-50.60)0.482Alanine aminotransferase (U/L)3120.06 (7.74-176.68)31824.34 (4.23-613.24)0.396Aspartate aminotransferase (U/L)3130.73 (9.74-143.00)31834.33 (9.63-761.63)0.824Alkaline phosphatase (U/L)3188.23 (28.83-337.00)31894.40 (31.00-983.93)0.641γ-Glutamyl transpeptidase (U/L)3170.00 (10.00-1779.18)31842.64 (7.54-1283.02)0.121Blood urea nitrogen (mmol/L)315.85 (3.52-47.25)3145.31 (0.64-24.80)0.226Serum creatinine (μmol/L)3170.90 (42.82-267.63)31464.07 (23.83-178.55)0.228Potassium (mmol/L)314.01 (2.80-5.41)3173.86 (2.42-5.28)0.066Sodium (mmol/L)31138.00 (134.10-145.50)317138.90 (118.00-152.90)0.574Homocysteine (μmol/L)1610.49 (6.70-31.79)1709.16 (1.59-102.81)0.145Total cholesterol (mmol/L)203.68 (1.82-6.58)2083.11 (1.14-6.29)0.148Triglyceride (mmol/L)200.83 (0.41-6.22)2080.85 (0.35-4.81)0.661High-density lipoprotein (mmol/L)200.93 (0.47-1.39)2080.94 (0.24-2.29)0.766Low-density lipoprotein (mmol/L)202.12 (0.99-4.37)2081.65 (0.47-4.06)0.013Lipoproteinα (mg/L)2088.70 (17.90-466.40)20863.20 (3.60-911.40)0.108Prothrombin time (seconds)3115.30 (12.70-20.40)31415.70 (10.30-28.00)0.188International normalized ratio311.23 (0.99-1.75)3141.27 (0.89-2.77)0.164Activated partial thromboplastin time (seconds)3140.20 (19.80-53.80)31439.90 (23.10-71.30)0.808D-dimer (mg/L)191.32 (0.16-10.56)2520.86 (0.10-46.17)0.873Antithrombin III (%)1165.30 (40.00-84.00)11863.00 (21.00-123.00)0.933Protein C activity (%)657.30 (49.80-75.10)5459.65 (24.00-119.30)0.721Protein S activity (%)661.55 (55.60-73.30)5463.50 (20.70-123.60)0.873Child-Pugh score317.00 (5.00-10.00)3137.00 (5.00-13.00)0.837MELD score3110.46 (7.23-18.00)31210.41 (6.43-30.03)0.736Portal vein thrombosis318 (25.8%)31892 (28.9%)0.713LPV4 (12.9%)25 (7.9%)0.332RPV2 (6.5%)31 (9.7%)0.549MPV4 (12.9%)52 (16.4%)0.617Confluence of SMV and SV5 (16.1%)35 (11.0%)0.393SMV2 (6.5%)51 (16.0%)0.156SV0 (0.0%)13 (4.1%)0.251No. pts: number of patients; MELD: model for the end-stage liver diseases; LPV: left portal vein; RPV: right portal vein; MPV: main portal vein; SMV: superior mesenteric vein; SV: splenic vein.


## 3.3. Comparison between Cirrhotic Patients with Ischemic Stroke and Those without Stroke

Compared with the patients without stroke, those with ischemic stroke were significantly older (61.08 versus 54.21 years,p=0.002) and had significantly higher proportions of alcohol abuse (65.5% versus 43.7%, p=0.024), smoking (69.0% versus 42.5%, p=0.006), and arterial hypertension (37.9% versus 12.9%, p<0.001) and higher levels of white blood cell (4.90 versus 3.40×109/L, p<0.001), potassium (4.05 versus 3.86 mmol/L, p=0.047), and low-density lipoprotein (2.12 versus 1.65 mmol/L, p=0.008) (Table 2). There was no significant difference in the prevalence of portal vein thrombosis and location of portal vein thrombosis between patients with and without stroke.Table 2
Comparison between patients with ischemic stroke and those without stroke.
VariablesIschemic strokeNo strokep valueNo. ptsMedian (range) or frequency (percentage)No. ptsMedian (range) or frequency (percentage)Age (years)2961.08 (38.72-77.30)31854.21 (20.57-88.73)0.002Gender (male)2923 (79.3%)318230 (72.3%)0.418Systolic blood pressure (mmHg)29124.00 (90.00-173.00)317122.00 (83.00-193.00)0.975Diastolic blood pressure (mmHg)2973.00 (50.00-108.00)31775.00 (34.00-118.00)0.700Etiology of liver diseasesHepatitis B virus infection2910 (34.5%)318125 (39.3%)0.610Hepatitis C virus infection291 (3.4%)31820 (6.3%)0.539Alcohol abuse2919 (65.5%)318139 (43.7%)0.024Drug related294 (13.8%)31821 (6.6%)0.152Budd-Chiari syndrome290 (0.0%)3181 (0.3%)0.762Autoimmune liver diseases290 (0.0%)31822 (6.9%)0.143Clinical presentations at admissionHepatic encephalopathy291 (3.4%)3188 (2.5%)0.762Acute gastrointestinal bleeding298 (27.6%)318101 (31.8%)0.643Ascites (no/mild/moderate-severe)2915 (51.7%)/7 (24.1%)/7 (24.1%)318127 (39.9%)/108 (34.0%)/83 (26.1%)0.424HistoryHistory of venous thrombus290 (0.0%)3187 (2.2%)0.420History of hematological diseases291 (3.4%)3185 (1.6%)0.458History of diabetes mellitus298 (27.6%)31851 (16.0%)0.113History of arterial hypertension2911 (37.9%)31841 (12.9%)<0.001History of smoking2920 (69.0%)318135 (42.5%)0.006History of cardiac diseases295 (17.2%)31823 (7.2%)0.058Laboratory testsRed blood cell (1012/L)293.33 (1.15-5.20)3183.27 (1.45-5.46)0.471Hemoglobin (g/L)29101.00 (37.00-174.00)31892.50 (28.00-156.00)0.126White blood cell (109/L)294.90 (1.30-22.70)3183.40 (0.70-20.80)<0.001Platelet (109/L)2990.00 (37.00-377.00)31873.00 (19.00-470.00)0.068Total bilirubin (μmol/L)2925.10 (5.70-132.70)31822.00 (5.20-281.10)0.606Direct bilirubin (μmol/L)299.00 (2.00-78.20)3189.45 (2.00-210.40)0.892Indirect bilirubin (μmol/L)2912.40 (3.60-76.00)31811.30 (3.20-93.80)0.576Albumin (g/L)2931.10 (22.10-44.50)31632.35 (14.20-50.60)0.401Alanine aminotransferase (U/L)2921.33 (7.74-176.68)31824.34 (4.23-613.24)0.643Aspartate aminotransferase (U/L)2931.44 (9.74-143.00)31834.33 (9.63-761.63)0.902Alkaline phosphatase (U/L)2992.49 (28.83-337.00)31894.40 (31.00-983.93)0.921γ-Glutamyl transpeptidase (U/L)2970.00 (10.00-1779.18)31842.64 (7.54-1283.02)0.073Blood urea nitrogen (mmol/L)295.82 (3.52-47.25)3145.31 (0.64-24.80)0.271Serum creatinine (μmol/L)2970.90 (42.82-267.63)31464.07 (23.83-178.55)0.253Potassium (mmol/L)294.05 (2.80-5.41)3173.86 (2.42-5.28)0.047Sodium (mmol/L)29137.90 (134.10-145.50)317138.90 (118.00-152.90)0.430Homocysteine (μmol/L)1510.47 (6.70-31.79)1709.16 (1.59-102.81)0.179Total cholesterol (mmol/L)193.77 (1.82-6.58)2083.11 (1.14-6.29)0.104Triglyceride (mmol/L)190.86 (0.47-6.22)2080.85 (0.35-4.81)0.414High-density lipoprotein (mmol/L)190.92 (0.47-1.39)2080.94 (0.24-2.29)0.762Low-density lipoprotein (mmol/L)192.12 (0.99-4.37)2081.65 (0.47-4.06)0.008Lipoproteinα (mg/L)1991.70 (17.90-466.40)20863.20 (3.60-911.40)0.114Prothrombin time (seconds)2915.30 (12.70-20.40)31415.70 (10.30-28.00)0.198International normalized ratio291.23 (0.99-1.75)3141.27 (0.89-2.77)0.170Activated partial thromboplastin time (seconds)2940.00 (19.80-53.80)31439.90 (23.10-71.30)0.952D-dimer (mg/L)191.32 (0.16-10.56)2520.86 (0.10-46.17)0.873Antithrombin III (%)1165.30 (40.00-84.00)11863.00 (21.00-123.00)0.933Protein C activity (%)657.30 (49.80-75.10)5459.65 (24.00-119.30)0.721Protein S activity (%)661.55 (55.60-73.30)5463.50 (20.70-123.60)0.873Child-Pugh score297.00 (5.00-10.00)3137.00 (5.00-13.00)0.749MELD score2910.46 (7.23-18.00)31210.41 (6.43-30.03)0.892Portal vein thrombosis297 (24.1%)31892 (28.9%)0.584LPV3 (10.3%)25 (7.9%)0.638RPV2 (6.9%)31 (9.7%)0.616MPV4 (13.8%)52 (16.4%)0.720Confluence of SMV and SV5 (17.2%)35 (11.0%)0.314SMV2 (6.9%)51 (16.0%)0.190SV0 (0.0%)13 (4.1%)0.267No. pts: number of patients; MELD: model for the end-stage liver diseases; LPV: left portal vein; RPV: right portal vein; MPV: main portal vein; SMV: superior mesenteric vein; SV: splenic vein.


## 3.4. PSM Analysis between Cirrhotic Patients with Ischemic Stroke and Those without Stroke

Twenty-eight patients were matched in each group after a 1 : 1 PSM analysis (Table3). There was no significant difference in demographics, etiology of liver disease, laboratory tests, clinical presentations, Child-Pugh score, and MELD score between the two groups. Notably, we still did not find any significant association between ischemic stroke and portal vein thrombosis.Table 3
Characteristics of cirrhotic patients with ischemic stroke and those without stroke after propensity score matching.
VariablesOverall (n=56)Ischemic stroke (n=28)No stroke (n=28)p valueAge (years)59.68 (35.18-77.30)60.65 (38.72-77.30)58.44 (35.18-75.72)0.258Gender (male)47 (83.9%)22 (78.6%)25 (89.3%)0.275Systolic blood pressure (mmHg)125.00 (83.00-173.00)124.50 (90.00-173.00)126.50 (83.00-158.00)0.491Diastolic blood pressure (mmHg)75.50 (44.00-108.00)72.00 (50.00-108.00)81.00 (44.00-107.00)0.161Etiology of liver diseasesHepatitis B virus infection23 (41.1%)10 (35.7%)13 (46.4%)0.415Hepatitis C virus infection1 (1.8%)1 (3.6%)0 (0.0%)0.313Alcohol abuse35 (62.5%)18 (64.3%)17 (60.7%)0.783Drug related6 (10.7%)4 (14.3%)2 (7.1%)0.388Budd-Chiari syndrome0 (0.0%)0 (0.0%)0 (0.0%)NAAutoimmune liver diseases1 (1.8%)0 (0.0%)1 (3.6%)0.313Clinical presentations at admissionHepatic encephalopathy2 (3.6%)1 (3.6%)1 (3.6%)1.000Acute gastrointestinal bleeding13 (23.2%)7 (25.0%)6 (21.4%)0.752Ascites (no/mild/moderate-severe)27 (48.2%)/14 (25.0%)/15 (26.8%)15 (53.6%)/6 (21.4%)/7 (25.0%)12 (42.9%)/8 (28.6%)/8 (28.6%)0.710HistoryHistory of venous thrombus0 (0.0%)0 (0.0%)0 (0.0%)NAHistory of hematological diseases1 (1.8%)1 (3.6%)0 (0.0%)0.313History of diabetes mellitus12 (21.4%)8 (28.6%)4 (14.3%)0.193History of arterial hypertension13 (23.2%)10 (35.7%)3 (10.7%)0.027History of smoking39 (69.6%)20 (71.4%)19 (67.9%)0.771History of cardiac diseases8 (14.3%)5 (17.9%)3 (10.7%)0.445Laboratory testsRed blood cell (1012/L)3.52 (1.15-5.20)3.34 (1.15-5.20)3.69 (1.74-5.08)0.456Hemoglobin (g/L)109.00 (37.00-174.00)102.00 (37.00-174.00)110.50 (58.00-156.00)0.812White blood cell (109/L)4.25 (1.30-22.70)4.70 (1.30-22.70)4.05 (1.30-20.80)0.063Platelet (109/L)84.50 (37.00-423.00)88.00 (37.00-377.00)75.00 (37.00-423.00)0.961Total bilirubin (μmol/L)24.25 (5.70-132.70)25.30 (5.70-132.70)24.15 (6.60-47.00)0.718Direct bilirubin (μmol/L)9.55 (2.00-78.20)9.30 (2.00-78.20)9.60 (2.50-27.00)0.961Indirect bilirubin (μmol/L)12.45 (3.60-76.00)12.60 (3.60-76.00)12.35 (4.10-27.70)0.967Albumin (g/L)32.55 (22.10-46.20)30.75 (22.10-44.50)33.95 (24.50-46.20)0.201Alanine aminotransferase (U/L)24.79 (7.53-176.68)21.66 (7.74-176.68)25.59 (7.53-140.00)0.793Aspartate aminotransferase (U/L)33.94 (9.74-166.49)34.22 (9.74-143.00)33.94 (13.94-166.49)0.857Alkaline phosphatase (U/L)98.86 (28.83-337.00)93.60 (28.83-337.00)102.83 (52.28-337.00)0.481γ-Glutamyl transpeptidase (U/L)60.87 (10.00-1779.18)69.50 (10.00-1779.18)56.00 (10.93-552.26)0.611Blood urea nitrogen (mmol/L)5.62 (2.96-47.25)5.81 (3.52-47.25)5.38 (2.96-20.15)0.502Serum creatinine (μmol/L)66.64 (42.82-267.63)68.96 (42.82-267.63)64.19 (44.50-117.53)0.870Potassium (mmol/L)3.99 (2.74-5.41)4.03 (2.80-5.41)3.89 (2.74-4.75)0.517Sodium (mmol/L)138.50 (133.50-145.50)137.95 (134.10-145.50)139.65 (133.50-145.20)0.210Prothrombin time (seconds)15.30 (12.70-20.40)15.30 (12.70-20.40)15.25 (12.00-18.90)0.774International normalized ratio1.24 (0.93-1.75)1.24 (0.99-1.75)1.24 (0.93-1.64)0.883Activated partial thromboplastin time (seconds)40.10 (19.80-53.80)40.10 (19.80-53.80)40.30 (27.50-50.80)0.961Child-Pugh score7.00 (5.00-10.00)7.00 (5.00-10.00)7.00 (5.00-13.00)0.259MELD score10.43 (6.43-18.00)10.52 (7.23-18.00)10.32 (6.43-15.58)0.676Portal vein thrombosis14 (25.0%)7 (25.0%)7 (25.0%)1.000MELD: model for the end-stage liver diseases.


## 4. Discussion

Recently, a large population-based cohort study using Danish National Patient Registry demonstrated that splanchnic vein thrombosis significantly increased the risk of bleeding and arterial cardiovascular events as compared to patients with venous thromboembolism and general population [23]. In this study, splanchnic vein thrombosis referred to venous thrombosis within the portal, hepatic, mesenteric, and splenic veins; and arterial cardiovascular events included unstable angina pectoris, acute myocardial infarction, and ischemic stroke. They included 1,915 patients with splanchnic vein thrombosis, of whom 1,711 patients had portal vein thrombosis. They found that patients with splanchnic vein thrombosis had higher risk of bleeding and arterial cardiovascular events up to 1 year after diagnosis. In contrast to these findings, we did not find any significant association between stroke and portal vein thrombosis in liver cirrhosis, even in the PSM analysis. There were several potential reasons for this unexpected phenomenon. First, HCV infection, which should be regarded as a possible causative factor in the antiphospholipid syndrome with an increased prevalence of anticardiolipin antibodies [24] and an aggravated risk of hypercoagulability, is more prevalent in Western countries; by comparison, in our Chinese patients, HBV infection is the major etiology of liver cirrhosis, and the prevalence of HCV infection was only 6.02% (21/349) in our patients, which might lead to a low probability of antiphospholipid syndrome. Second, because Helicobacter pylori is an indirect risk factor of hypercoagulation and is not routinely detected in liver cirrhosis, our study did not have such data and could not compare the difference in the prevalence of Helicobacter pylori infection between patients with and without stroke. Third, our study demonstrated that the level of homocysteine was higher in patients with stroke or ischemic stroke than in patients without stroke, but the difference was not significant. This finding should be validated by expanding the number of patients who underwent laboratory tests of homocysteine levels.Our study had several limitations. First, the number of our study population, especially patients with ischemic stroke, might not be adequate. Among the patients admitted to our Department of Gastroenterology, most of stroke events are usually asymptomatic. Therefore, in our retrospective observational study, the imaging examination of the brain has not been performed in every cirrhotic patient to evaluate the risk of asymptomatic stroke. Indeed, the imaging examination of the brain in every cirrhotic patient might not be approved by any ethical committee. Herein, the history of asymptomatic stroke, such as lacunar infarction, might be missed. Second, in the present study, we selected study population from a prospectively established database, in which only the patients undergoing enhanced computed tomography or magnetic resonance are included. Although enhanced computed tomography or magnetic resonance can evaluate more precisely the existence, extent, and degree of portal vein thrombosis, there was a potential bias in patient selection in this setting. Third, hypercoagulability is not evaluated in all patients. Fourth, Helicobacter pylori infection, which may be associated with both portal vein thrombosis and stroke, has not been studied in our study.In conclusion, our study could not establish any association between stroke and portal vein thrombosis in liver cirrhosis. Certainly, well-designed large-scale prospective cohort studies will be necessary to confirm this finding.



---

*Source: 8172673-2020-07-02.xml*